Next Article in Journal
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer
Previous Article in Journal
Multidisciplinary Pain Management of Chronic Back Pain: Helpful Treatments from the Patients’ Perspective
Open AccessArticle

Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations

1
Department of Nephrology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
2
Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
3
Tokyo Women’s Medical University, Tokyo 162-8666, Japan
4
Department of Blood Purification, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 146; https://doi.org/10.3390/jcm9010146 (registering DOI)
Received: 19 December 2019 / Accepted: 3 January 2020 / Published: 5 January 2020
(This article belongs to the Section Nephrology & Urology)
Autosomal dominant polycystic kidney disease (ADPKD) patients with PKD1 mutations, particularly those with truncating mutations, show poor prognosis. However, the differences in disease progression with different mutation types are unclear. Here, a comparative study was conducted on the renal prognosis of patients with ADPKD who were categorized based on genotype (PKD1 versus PKD2 mutation), mutation type (truncating mutation: nonsense, frameshift, splicing mutation, and large deletion; non-truncating mutation: substitution and in-frame deletion), and mutation position. A total of 123 patients visiting our hospital were enrolled. Renal prognosis was poor for those with PKD1 splicing, PKD1 frameshift, and PKD2 splicing mutations. Despite the truncating mutation, the renal prognosis was relatively favorable for patients with nonsense mutations. Three out of five patients with PKD2 mutation required renal replacement therapy before 58 years of age. In conclusion, we showed that renal prognosis differs according to mutation types in both PKD1 and PKD2, and that it was favorable for those with nonsense mutations among patients with PKD1 truncating mutations. It was also confirmed that renal prognosis was not always favorable in patients with PKD2 mutations. A detailed assessment of mutation types may be useful for predicting the renal prognosis of patients with ADPKD. View Full-Text
Keywords: polycystic kidney disease; PKD1; PKD2; mutation; renal prognosis; renal progression polycystic kidney disease; PKD1; PKD2; mutation; renal prognosis; renal progression
Show Figures

Figure 1

MDPI and ACS Style

Kataoka, H.; Fukuoka, H.; Makabe, S.; Yoshida, R.; Teraoka, A.; Ushio, Y.; Akihisa, T.; Manabe, S.; Sato, M.; Mitobe, M.; Tsuchiya, K.; Nitta, K.; Mochizuki, T. Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations. J. Clin. Med. 2020, 9, 146.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop